08:04 AM EDT, 10/21/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said late Friday that its eye disease drug Eylea HD showed continued durable vision gains and anatomic improvements in most of the patients with diabetic macular edema in a phase 3 extension study.

The company said slower fluid reaccumulation was noted in patients who switched to Eylea HD injection 8 mg following their first dose while achieving longer treatment intervals, supporting the longer duration of action of Eylea HD compared with Eylea.

The safety profile of Eylea HD remained "generally consistent" with previous trials, with common ocular adverse events including cataract, vitreous floaters, and diabetic retinal edema. No cases of occlusive retinal vasculitis were reported.

Eylea HD is being jointly developed by Regeneron and Bayer, with Regeneron holding exclusive rights to Eylea and Eylea HD in the US.

Price: 987.28, Change: -3.40, Percent Change: -0.34